Semaglutide vs. Phentermine: Which Weight Loss Medication Actually Works?

Phentermine has been around since the 1950s. Semaglutide launched in 2021. For anyone researching weight loss medications, this comparison is one of the most important they can make — because these drugs work through completely different mechanisms and deliver very different outcomes.

Here's the honest breakdown.

How Each Drug Works

Phentermine is a stimulant — chemically similar to amphetamine — that suppresses appetite by releasing norepinephrine in the brain. It's a short-term intervention: FDA-approved for up to 12 weeks, classified as a controlled substance (Schedule IV), and its effects plateau quickly as the body adapts. Phentermine is also one of the most commonly prescribed weight loss medications in the US by volume, largely because of cost.

Semaglutide (brand names: Ozempic for diabetes, Wegovy for obesity) is a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone your gut naturally releases after eating. It signals satiety to the hypothalamus, slows gastric emptying, and reduces appetite through a physiologically direct mechanism — not stimulant-driven central nervous system activation. It's injected weekly.

What the Clinical Data Says

The comparison isn't subtle:

Weight loss at 68 weeks: - Semaglutide 2.4mg (STEP 1 trial): −14.9% of body weight on average. ~1 in 3 patients lost >20% of body weight. - Phentermine (typical 12-week course): −3% to −5% of body weight, with most regain occurring after stopping.

Sustainability: - Semaglutide's effects persist with continued treatment; STEP 4 showed that patients who stopped regained two-thirds of their lost weight within a year. - Phentermine provides short-term suppression; tolerance develops rapidly, often within weeks, and it's not approved for long-term use.

Cardiovascular outcomes: - Semaglutide has demonstrated cardiovascular benefit in clinical trials (SELECT trial: 20% reduction in major adverse cardiovascular events). - Phentermine carries cardiovascular warnings — particularly for patients with hypertension, heart disease, or arrhythmias. Its use in cardiac-risk patients requires careful evaluation.

Side Effect Profiles

Semaglutide side effects: - Nausea, vomiting, and diarrhea — primarily during dose escalation - Most resolve after the first 4–8 weeks - Rare: pancreatitis, gallbladder disease, injection site reactions - Contraindicated in personal/family history of MTC (thyroid cancer) and MEN2

Phentermine side effects: - Elevated heart rate and blood pressure - Insomnia, restlessness, anxiety, dry mouth - Potential for dependence and misuse (controlled substance classification) - Cardiac risks in predisposed individuals

Who Should Use Which?

Phentermine may make sense if: - You need a short-term kickstart (few weeks, with structured diet/exercise program) - Cost is the primary constraint — phentermine is generic and often $20–$30/month - You've discussed cardiac history with a physician and it's appropriate

Semaglutide is typically the better choice if: - You're looking for sustained, clinically meaningful weight loss (>10% of body weight) - You have type 2 diabetes or prediabetes (where GLP-1 has independent metabolic benefits) - You have cardiovascular risk factors - You want a treatment that aligns with your physiology rather than overriding it with stimulant effects - You're willing to invest in long-term intervention

The Cost Reality

This is where phentermine wins by default for many patients. Phentermine is $20–$50/month. Branded Wegovy is $1,300–$1,500/month without insurance. Compounded semaglutide from providers like Marrow is $199–$299/month — which changes the math significantly.

At $199/month for compounded semaglutide versus $30/month for phentermine, the delta is $169/month. But if semaglutide produces 3-4x the weight loss and the results are durable with continued treatment, the cost-effectiveness calculation often favors semaglutide.

Can You Use Both?

Combination therapy (phentermine + topiramate) is an FDA-approved combination sold as Qsymia. Combining phentermine with GLP-1 medications is generally not standard practice and has less evidence — it's not a combination most physicians would routinely prescribe.

The Bottom Line

Phentermine is a decades-old stimulant with modest short-term effects and significant limitations. Semaglutide is a mechanistically different drug with substantially better clinical outcomes across virtually every measured endpoint — weight loss magnitude, durability, cardiovascular benefit.

The reason phentermine is still commonly prescribed is cost and familiarity, not because it's a better drug.

For most patients with meaningful weight loss goals, semaglutide — whether branded or compounded — represents the current standard of care. Marrow offers compounded semaglutide starting at $199/month, with physician oversight and full monitoring protocol included.